MYL3 as A Potential Drug Target for MCL (G4634)

Target Name: MYL3

NCBI ID: G4634

MYL3

MYL3 as A Potential Drug Target for MCL

Myeloid-derived lymphoma (MCL) is a type of blood cancer that originates from the myeloid lineage of the immune system. MCL is a aggressive and rare type of cancer, with few effective treatment options. The development of drug resistance and the lack of specific biomarkers make the treatment of MCL a significant challenge.

One potential drug target for MCL is MYL3 ( Short for Myeloid-derived Lymphoma 3), a gene that is expressed in the myeloid cells and is associated with the development and progression of MCL.MYL3 has been shown to be overexpressed in MCL samples and has been identified as a potential biomarker for the disease.

TheMYL3 gene encodes a protein that is involved in the development and maintenance of myeloid cells. It is a key regulator of the myeloid lineage and has been shown to play a role in the development of MCL.MYL3 has been shown to promote the growth and survival of myeloid cells, and it has been implicated in the development of MCL.

In addition to its role in the development of MCL,MYL3 has also been shown to be a potential drug target for the disease. Several studies have shown that inhibiting MYL3 can lead to the regression of MCL tumors. This is because MYL3 is involved in the production of a signaling molecule called Src, which is a key regulator of cell growth and survival. By inhibiting Src, researchers have been able to reduce the growth and spread of MCL tumors.

Another potential mechanism by which MYL3 may contribute to the development and progression of MCL is its role in the regulation of the immune response. MCL tumors have been shown to evade the immune response, allowing them to persist and multiply.MYL3 has been shown to be involved in the regulation of the immune response by inhibiting the activity of a protein called T-cell dependent killer (TK).

TK is a key regulator of the immune response and has been shown to play a role in the development and progression of MCL. It is a protein that is expressed in T cells and is involved in the destruction of cancer cells. By inhibiting TK, researchers have been able to enhance the immune response against MCL tumors.

In conclusion, MYL3 is a potential drug target for MCL due to its involvement in the development and progression of the disease. TheMYL3 gene has been shown to promote the growth and survival of myeloid cells, and it has been implicated in the regulation of the immune response. Further research is needed to fully understand the role of MYL3 in MCL and to develop effective treatments for this disease.

Protein Name: Myosin Light Chain 3

Functions: Regulatory light chain of myosin. Does not bind calcium

The "MYL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MYL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets